retatrutide peptide forum isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and Drug Retatrutide Weight Loss: Complete Protocol

The 11.2% discontinuation rate at highest dose is similar to tirzepatide (6-9%) and better than earlier GLP-1 medications

This pudding works just as well half-eaten as it does fully finished, which makes it a solid small-meal option when appetite varies

Its important to note that no changes have been made to the meals themselves

I joined a Discord that I found from Reddit of peptide enthusiasts

Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation

Your body is adjusting